Venetoclax–based low intensity therapy in molecular failure of <i>NPM1</i>-mutated AML
Carlos Jiménez‐Chillón(King's College London), Richard Dillon(King's College London), Manish Jain(Leeds Teaching Hospitals NHS Trust), Seda Cakmak(St Bartholomew's Hospital), James Aries(Queen Mary University of London), Andrew H. Wei(The University of Melbourne), Martin Jädersten(Karolinska University Hospital), Jane E. Parker(Cluster of Excellence on Plant Sciences), Anne Stidsholt Roug(Aalborg University Hospital), Alexandra Martínez‐Roca(Hospital Clínic de Barcelona), Jordi Esteve(Hospital Clínic de Barcelona), Anne Parker(Queen Elizabeth University Hospital), Daniel Tuyet Kristensen(Aalborg University Hospital), Carlos Jiménez‐Vicente(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Ing Soo Tiong(Peter MacCallum Cancer Centre), Katya Mokretar, Nigel H. Russell(Nottingham University Hospitals NHS Trust), David Taussig(Institute of Cancer Research), Cara Manson(Queen Elizabeth University Hospital), Charlotte Kallmeyer(Lincoln County Hospital), Jad Othman(King's College London), David Veale(Royal Devon & Exeter NHS Foundation Trust), Nina Orfali(St. James's Hospital), Thomas Erblich(London Clinic), Ulrik Malthe Overgaard(Copenhagen University Hospital), Vidhya Murthy(NIHR Surgical Reconstruction and Microbiology Research Centre), Nicola Potter(European Bioinformatics Institute), Simon Bolam(Taunton & Somerset NHS Foundation Trust), Joy Zacharoula Galani(Dartford And Gravesham NHS Trust), Deborah Richardson(University Hospital Southampton NHS Foundation Trust), Loretta Ngu(Royal Devon & Exeter NHS Foundation Trust), Steven Knapper(Cardiff University)
Cited by 29
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k